Federation des caisses Desjardins du Quebec’s Summit Therapeutics SMMT Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$134K	Buy	9,176 +295	+3%	+$5.23K	﹤0.01%	1689
2026 Q1	$168K	Buy	8,881 +268	+3%	+$4.33K	﹤0.01%	1566
2025 Q4	$151K	Sell	8,613 -690	-7%	-$13K	﹤0.01%	1568
2025 Q3	$192K	Buy	+9,303	New	+$226K	﹤0.01%	1484

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's SMMT Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec increased its Summit Therapeutics (SMMT) stake by 3.3% in Q2 2026, buying an estimated $5.23K and bringing the position to 9,176 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #1689.

Federation des caisses Desjardins du Quebec first reported a position in SMMT in Q3 2025 and has held it in 4 quarters since. The position peaked at $192K in Q3 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Federation des caisses Desjardins du Quebec held 9,176 shares of Summit Therapeutics worth $134K as of Q2 2026.
Federation des caisses Desjardins du Quebec bought 295 Summit Therapeutics shares in Q2 2026, an estimated $5.23K.
Summit Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #1689 holding.
Federation des caisses Desjardins du Quebec first reported a position in Summit Therapeutics in Q3 2025 and has held it in 4 quarters since.
Federation des caisses Desjardins du Quebec's Summit Therapeutics position peaked at $192K in Q3 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.